Entity Details

Primary name SCN3A_HUMAN
Entity type UniProt
Source Source Link

Details

AccessionQ9NY46
EntryNameSCN3A_HUMAN
FullNameSodium channel protein type 3 subunit alpha
TaxID9606
Evidenceevidence at protein level
Length2000
SequenceStatuscomplete
DateCreated2001-02-21
DateModified2021-06-02

Ontological Relatives

GenesSCN3A

GO terms

Show/Hide Table
GOName
GO:0001518 voltage-gated sodium channel complex
GO:0005244 voltage-gated ion channel activity
GO:0005248 voltage-gated sodium channel activity
GO:0005737 cytoplasm
GO:0006814 sodium ion transport
GO:0019228 neuronal action potential
GO:0030424 axon
GO:0034765 regulation of ion transmembrane transport
GO:0035725 sodium ion transmembrane transport
GO:0086010 membrane depolarization during action potential

Subcellular Location

Show/Hide Table
Subcellular Location
Cell membrane

Domains

Show/Hide Table
DomainNameCategoryType
IPR000048 IQ motif, EF-hand binding siteSiteBinding site
IPR001696 Voltage gated sodium channel, alpha subunitFamilyFamily
IPR005821 Ion transport domainDomainDomain
IPR010526 Sodium ion transport-associatedDomainDomain
IPR024583 Voltage-gated Na+ ion channel, cytoplasmic domainDomainDomain
IPR027359 Voltage-dependent channel domain superfamilyFamilyHomologous superfamily
IPR043203 Voltage-gated cation channel calcium and sodiumFamilyFamily
IPR044564 Voltage-gated sodium channel alpha subunit, inactivation gateDomainDomain

Diseases

Show/Hide Table
Disease IDSourceNameDescription
617935 OMIMEpilepsy, familial focal, with variable foci 4 (FFEVF4)An autosomal dominant form of epilepsy characterized by focal seizures arising from different cortical regions, including the temporal, frontal, parietal, and occipital lobes. Seizure types commonly include temporal lobe epilepsy, frontal lobe epilepsy, and nocturnal frontal lobe epilepsy. Some patients may have intellectual disability or autism spectrum disorders. Seizure onset usually occurs in the first or second decades, although later onset has been reported, and there is phenotypic variability within families. A subset of patients have structural brain abnormalities. Penetrance of the disorder is incomplete. FFEVF4 is characterized by onset of focal seizures in the first years of life. The disease is caused by variants affecting the gene represented in this entry.
617938 OMIMDevelopmental and epileptic encephalopathy 62 (DEE62)A form of epileptic encephalopathy, a heterogeneous group of severe childhood onset epilepsies characterized by refractory seizures, neurodevelopmental impairment, and poor prognosis. Development is normal prior to seizure onset, after which cognitive and motor delays become apparent. DEE62 is characterized by onset of seizures in the first year of life. The disease is caused by variants affecting the gene represented in this entry.

Drugs

Show/Hide Table
DrugNameSourceType
DB00243 RanolazineDrugbanksmall molecule
DB00252 PhenytoinDrugbanksmall molecule
DB00273 TopiramateDrugbanksmall molecule
DB00313 Valproic acidDrugbanksmall molecule
DB00555 LamotrigineDrugbanksmall molecule
DB00564 CarbamazepineDrugbanksmall molecule
DB00776 OxcarbazepineDrugbanksmall molecule
DB00907 CocaineDrugbanksmall molecule
DB00909 ZonisamideDrugbanksmall molecule
DB01069 PromethazineDrugbanksmall molecule
DB05232 TetrodotoxinDrugbanksmall molecule
DB05541 BrivaracetamDrugbanksmall molecule
DB06218 LacosamideDrugbanksmall molecule
DB09085 TetracaineDrugbanksmall molecule
DB09088 AmylocaineDrugbanksmall molecule
DB09342 PropoxycaineDrugbanksmall molecule
DB09345 PramocaineDrugbanksmall molecule
DB11186 PentoxyverineDrugbanksmall molecule
DB13269 Dichlorobenzyl alcoholDrugbanksmall molecule
DB13746 BioallethrinDrugbanksmall molecule
DB13961 Fish oilDrugbankbiotech

Interactions

5 interactions